The Efficacy and Safety of Switch Between Agalsidase Beta to Agalsidase Alfa for Enzyme Replacement in Patients With Anderson-Fabry Disease
Clinical trial NCT01268241 · COMPLETED
Trial details
- NCT number
- NCT01268241
- Sponsor
- CENTOGENE GmbH Rostock
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2010-12-01
- Primary completion
- 2016-04-01
- Enrollment
- 200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.